Association of systemic immune-inflammation-index with all-cause and cause-specific mortality among type 2 diabetes: a cohort study base on population.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Humana Press Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE
    • Publication Information:
      Publication: Feb. 1996- : Totowa, NJ : Humana Press
      Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/mortality ; Diabetes Mellitus, Type 2*/immunology ; Nutrition Surveys* ; Inflammation*/mortality ; Inflammation*/blood ; Cause of Death*; Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Cohort Studies ; United States/epidemiology ; Cardiovascular Diseases/mortality ; Biomarkers/blood ; Platelet Count
    • Abstract:
      Purpose: There have been limited studies examining the prospective association between the Systemic Immune-Inflammation Index (SII), a novel inflammatory marker, and mortality among individuals with diabetes in the United States.
      Methods: We utilized data from the National Health and Nutrition Examination Survey (NHANES), a representative sample of US adults, linked with information from the National Death Index.
      Results: Our study included 8697 individuals from NHANES spanning the years 1999 to 2018. SII was calculated by dividing the platelet count by the neutrophil count and then dividing that result by the lymphocyte count. We employed multivariable Cox proportional hazards regression analysis to investigate the associations between SII levels and all-cause as well as cause-specific mortality, while adjusting for potential confounding factors. SII levels were categorized into quartiles based on the study population distribution. Over a median follow-up period of 94.8 months (with a maximum of 249 months), we observed a total of 2465 all-cause deaths, 853 deaths from cardiovascular causes, 424 deaths from cancer, and 88 deaths related to chronic kidney disease. After adjusting for multiple variables, higher SII levels were significantly and non-linearly associated with an increased risk of all-cause mortality in Quartile 4 (HR 1.74, 95% CI 1.15-2.63, P for trend = 0.043) when Quartile 1 was used as the reference group. Additionally, we identified a linear association between SII and cardiovascular mortality, with a 70% higher risk of cardiovascular mortality in Quartile 4 (HR 1.70, 95% CI 1.18-3.30, P for trend = 0.041) compared to Quartile 1.
      Conclusion: Our findings indicate that SII is significantly associated with an elevated risk of all-cause and cardiovascular mortality in US adults with diabetes.
      (© 2023. The Author(s).)
    • References:
      Nat Rev Endocrinol. 2022 Jan;18(1):23-42. (PMID: 34703027)
      Immunity. 2022 Jan 11;55(1):31-55. (PMID: 35021057)
      Ann Intern Med. 2019 May 7;170(9):604-613. (PMID: 30959527)
      Hepatology. 2022 Jun;75(6):1491-1506. (PMID: 34668597)
      Cell Mol Immunol. 2021 May;18(5):1141-1160. (PMID: 33850310)
      Ann Surg. 2019 Jul;270(1):139-146. (PMID: 29334554)
      Nat Rev Immunol. 2022 Apr;22(4):251-265. (PMID: 34389841)
      Clin Cancer Res. 2014 Dec 1;20(23):6212-22. (PMID: 25271081)
      Diabetologia. 2016 Mar;59(3):512-21. (PMID: 26634571)
      Nat Rev Immunol. 2019 Dec;19(12):734-746. (PMID: 31501536)
      JAMA Netw Open. 2022 Jan 4;5(1):e2146124. (PMID: 35099545)
      World J Gastroenterol. 2017 Sep 14;23(34):6261-6272. (PMID: 28974892)
      Inflammation. 2018 Mar;41(2):626-642. (PMID: 29264745)
      Lancet. 2021 Dec 19;396(10267):2019-2082. (PMID: 33189186)
      Diabetes Res Clin Pract. 2014 Aug;105(2):141-50. (PMID: 24798950)
      Biomed Res Int. 2018 Nov 11;2018:2703518. (PMID: 30534554)
      Inflamm Res. 2023 Jan;72(1):149-158. (PMID: 36352033)
      Trends Immunol. 2004 Jan;25(1):4-7. (PMID: 14698276)
      Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
      Int J Cardiol. 2017 Dec 1;248:349-354. (PMID: 28712557)
      Clin Interv Aging. 2021 Jan 11;16:97-105. (PMID: 33469277)
      J Clin Invest. 2006 Jul;116(7):1793-801. (PMID: 16823477)
      Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977)
      Int J Cancer. 2020 Feb 1;146(3):692-698. (PMID: 30924141)
      J Clin Lab Anal. 2018 Feb;32(2):. (PMID: 28378887)
      JAMA. 2018 Nov 20;320(19):2020-2028. (PMID: 30418471)
      BMC Cancer. 2021 May 18;21(1):569. (PMID: 34006248)
      Clin Chem Lab Med. 2016 Dec 1;54(12):1963-1969. (PMID: 27010778)
      Atherosclerosis. 2021 Apr;323:20-29. (PMID: 33773161)
      Eur J Clin Invest. 1992 Oct;22 Suppl 1:10-5. (PMID: 1333964)
    • Grant Information:
      82004341 National Natural Science Foundation of China
    • Contributed Indexing:
      Keywords: All-cause mortality; Cardiovascular mortality; NHANES; Population-based study; Prospective cohort study; Systemic immune-inflammation index
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20231204 Date Completed: 20240507 Latest Revision: 20240510
    • Publication Date:
      20240510
    • Accession Number:
      PMC11076376
    • Accession Number:
      10.1007/s12020-023-03587-1
    • Accession Number:
      38048013